Oncopeptides (ONCO) Panoramica del titolo
Oncopeptides AB (publ), azienda biotecnologica, è impegnata nella ricerca, nello sviluppo e nella commercializzazione di terapie mirate per malattie ematologiche difficili da trattare negli Stati Uniti, in Europa e a livello internazionale. Maggiori dettagli
| Punteggio fiocco di neve | |
|---|---|
| Valutazione | 3/6 |
| Crescita futura | 2/6 |
| Prestazioni passate | 0/6 |
| Salute finanziaria | 5/6 |
| Dividendi | 0/6 |
Premi
Analisi del rischio
ONCO Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Top Community Narratives
SEK 2.56
FV
38.4% sottovalutato sconto intrinseco63
users have viewed this narrative0users have liked this narrative
1users have commented on this narrative
4users have followed this narrative
Concorrenti di Oncopeptides AB (publ)
Storia dei prezzi e prestazioni
| Prezzi storici delle azioni | |
|---|---|
| Prezzo attuale dell'azione | SEK 1.58 |
| Massimo di 52 settimane | SEK 6.55 |
| Minimo di 52 settimane | SEK 1.26 |
| Beta | -1.33 |
| Variazione di 1 mese | -1.74% |
| Variazione a 3 mesi | -7.83% |
| Variazione di 1 anno | -66.06% |
| Variazione a 3 anni | -76.77% |
| Variazione a 5 anni | -95.90% |
| Variazione dall'IPO | -96.33% |
Notizie e aggiornamenti recenti
Aggiornamento narrativa • Jul 09
ONCO: Expanded Multiple Myeloma Reach Will Drive Future Risk Reward Repricing
Analysts have cut their price target on Oncopeptides to SEK2.10 from SEK4.50, citing updated assumptions for fair value, a higher discount rate, more moderate revenue growth, and a higher projected profit margin paired with a lower future P/E multiple. What’s in the News for Oncopeptides Oncopeptides enrolled the first patient in the OP-701 INSULA "Window of Opportunity" study in glioblastoma, the first clinical evaluation of its peptide drug conjugate platform in this indication.
Aggiornamento narrativa • Jun 25
ONCO: Expanded Multiple Myeloma Indication Will Drive Long-Term Upside
Analysts have adjusted their price target on Oncopeptides to SEK 3.10 from SEK 5.50, citing updated assumptions around fair value, discount rate, revenue growth, profit margin and future P/E. What's in the News for Oncopeptides First patient enrolled in the OP-701 INSULA "Window-of-Opportunity" study in glioblastoma, the first clinical evaluation of Oncopeptides' PDC platform in this cancer, aiming to assess blood brain barrier penetration and tumor cell activity; the trial is being conducted at Oslo University Hospital in Norway.Recent updates
Aggiornamento narrativa • Jul 09
ONCO: Expanded Multiple Myeloma Reach Will Drive Future Risk Reward Repricing
Analysts have cut their price target on Oncopeptides to SEK2.10 from SEK4.50, citing updated assumptions for fair value, a higher discount rate, more moderate revenue growth, and a higher projected profit margin paired with a lower future P/E multiple. What’s in the News for Oncopeptides Oncopeptides enrolled the first patient in the OP-701 INSULA "Window of Opportunity" study in glioblastoma, the first clinical evaluation of its peptide drug conjugate platform in this indication.Aggiornamento narrativa • Jun 25
ONCO: Expanded Multiple Myeloma Indication Will Drive Long-Term Upside
Analysts have adjusted their price target on Oncopeptides to SEK 3.10 from SEK 5.50, citing updated assumptions around fair value, discount rate, revenue growth, profit margin and future P/E. What's in the News for Oncopeptides First patient enrolled in the OP-701 INSULA "Window-of-Opportunity" study in glioblastoma, the first clinical evaluation of Oncopeptides' PDC platform in this cancer, aiming to assess blood brain barrier penetration and tumor cell activity; the trial is being conducted at Oslo University Hospital in Norway.
Aggiornamento narrativa • Apr 29
ONCO: Rights Issue And Glioblastoma Study Will Support Bullish Long Term View
Analysts have maintained their SEK fair value estimate for Oncopeptides at SEK 2.80, while fine tuning assumptions for the discount rate, profit margin, and future P/E. This reflects updated views on the company’s risk profile and earnings potential without changing the headline price target.Aggiornamento narrativa • Apr 12
ONCO: Rights Issue And New Studies Will Support Bullish Long Term View
Analysts have modestly adjusted their SEK price target for Oncopeptides, reflecting small refinements to discount rate, profit margin assumptions, and future P/E inputs rather than a shift in the core fair value view. What's in the News Oncopeptides plans to support the MARINA real world evidence study of Pepaxti in relapsed, refractory multiple myeloma in Germany, targeting around 50 patients across about 25 sites, with iOMEDICO as sponsor and coordinator and first patient enrolment planned for the second quarter of 2026 (Key Developments).Aggiornamento narrativa • Mar 28
ONCO: Rights Offering And 2025 Sales Guidance Will Support Bullish View
Analysts have kept their SEK price target for Oncopeptides effectively unchanged, pointing to stable fair value assumptions and only marginal tweaks to inputs such as the discount rate, forecast revenue growth, profit margin and future P/E multiple. What's in the News Oncopeptides has filed a follow on equity offering of Ordinary Shares, targeting SEK 200.4 million through a rights offering of 129,283,736 shares at SEK 1.55 per share (Key Developments).Aggiornamento narrativa • Mar 12
ONCO: Rights Issue And 2025 Sales Outlook Will Support Bullish View
Analysts have adjusted their price target on Oncopeptides to SEK 2.80. The change is largely tied to updated assumptions around the discount rate, profit margin, and future P/E, rather than a shift in estimated fair value.Aggiornamento narrativa • Feb 25
ONCO: Rights Issue And 2025 Sales Guidance Will Support Bullish Outlook
Analysts have trimmed their price target on Oncopeptides to SEK 2.80 from SEK 4.75, reflecting updated assumptions for slightly lower revenue growth, a marginally softer profit margin, a higher discount rate, and a reduced future P/E multiple. What's in the News Oncopeptides AB (publ) has filed a follow on equity offering of approximately SEK 200.4m through a rights offering of 129,283,736 ordinary shares at SEK 1.55 per share (Key Developments).Aggiornamento narrativa • Feb 09
ONCO: Future Sales Guidance Will Support Bullish View On Upcoming Results
Analysts have cut their price target on Oncopeptides to €4.75 from €5.50, reflecting updated assumptions around revenue growth, profit margins, a higher discount rate, and a higher future P/E multiple. What's in the News Oncopeptides issued sales guidance for the fourth quarter 2025.Aggiornamento narrativa • Jan 25
ONCO: NK Cell Platform Progress Will Drive Future Risk Reward Repricing
Analysts have reduced their price target for Oncopeptides from 5.0 to 4.5, reflecting a fair value adjustment driven by shifts in projected revenue growth, higher discount rates, stronger profit margin assumptions, and a lower future P/E estimate. What's in the News Oncopeptides issued sales guidance for the fourth quarter and full year 2025, with expected Q4 2025 net sales of SEK 18.6 million and full year 2025 net sales of SEK 71.2 million, both described by the company as higher compared with 2024 (Corporate guidance).Aggiornamento narrativa • Jan 11
ONCO: NK Cell Platform Progress And Expert Guidance Will Shape Future Risk Reward
Analysts have modestly lowered their future P/E assumption for Oncopeptides from 38.59x to 36.58x, keeping fair value at €5.00. They have fine tuned expectations for revenue growth and profit margins while making a slight adjustment to the discount rate.Aggiornamento narrativa • Dec 26
ONCO: Improved Profitability And NK Cell Platform Will Drive Long-Term Upside
Analysts have raised their price target on Oncopeptides from approximately SEK 4.50 to SEK 5.50 per share, citing expectations of stronger long term profitability, supported by higher projected profit margins and a lower future price to earnings multiple, despite slightly tempered revenue growth assumptions and a modestly higher discount rate. What's in the News Panel of leading multiple myeloma experts publishes clinical recommendations in Annals of Hematology on optimal use of Pepaxti (melflufen), reinforcing its role as an important option for relapsed, refractory multiple myeloma, including elderly and high risk patients, with a manageable safety profile (company announcement).Aggiornamento narrativa • Dec 12
ONCO: Future NK Platform And Equity Raise Will Shape Risk Reward Profile
Analysts have modestly raised their price target on Oncopeptides to align with a fair value approaching $5.00 per share, citing a higher required discount rate, more conservative revenue growth and margin assumptions, and a structurally higher future P/E multiple. Taken together, these factors imply a more cautiously optimistic risk reward profile.Aggiornamento narrativa • Aug 20
Agreements In Europe And Japan Will Unlock Global Markets
The notable increase in Oncopeptides' fair value target is primarily driven by a higher forecasted future P/E multiple, despite a marginal dip in revenue growth expectations, with the analyst consensus price target rising from SEK2.73 to SEK3.25. What's in the News Strategic partnership with SD Pharma enhances Pepaxti's hospital reach in Spain without upfront costs, starting Q3 2025.Articolo di analisi • Jul 28
A Look At The Fair Value Of Oncopeptides AB (publ) (STO:ONCO)
Key Insights Oncopeptides' estimated fair value is kr5.77 based on Dividend Discount Model Oncopeptides' kr6.00 share...
Nuova narrativa • Apr 15
Agreements In Europe And Japan Will Unlock Global Markets
Strategic agreements in Europe and potential licensing in Japan will unlock major markets, enhancing future earnings and revenue growth.Articolo di analisi • Jun 18
An Intrinsic Calculation For Oncopeptides AB (publ) (STO:ONCO) Suggests It's 45% Undervalued
Key Insights Using the Dividend Discount Model, Oncopeptides fair value estimate is kr5.43 Oncopeptides is estimated to...Articolo di analisi • Feb 29
Oncopeptides (STO:ONCO) Will Have To Spend Its Cash Wisely
Just because a business does not make any money, does not mean that the stock will go down. For example, although...Articolo di analisi • Nov 14
Oncopeptides (STO:ONCO) Has Debt But No Earnings; Should You Worry?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Rendimenti per gli azionisti
| ONCO | SE Biotechs | SE Mercato | |
|---|---|---|---|
| 7D | -1.5% | -1.5% | -1.0% |
| 1Y | -66.1% | 23.9% | 12.4% |
Ritorno vs Industria: ONCO ha avuto una performance inferiore rispetto al Swedish Biotechs che ha registrato un rendimento 23.9 % nell'ultimo anno.
Rendimento vs Mercato: ONCO ha avuto una performance inferiore al mercato Swedish che ha registrato un rendimento 12.4 % nell'ultimo anno.
Volatilità dei prezzi
| ONCO volatility | |
|---|---|
| ONCO Average Weekly Movement | 7.6% |
| Biotechs Industry Average Movement | 8.8% |
| Market Average Movement | 5.7% |
| 10% most volatile stocks in SE Market | 11.3% |
| 10% least volatile stocks in SE Market | 3.1% |
Prezzo delle azioni stabile: ONCO non ha avuto una volatilità dei prezzi significativa negli ultimi 3 mesi rispetto al mercato Swedish.
Volatilità nel tempo: La volatilità settimanale ( 8% ) di ONCO è rimasta stabile nell'ultimo anno.
Informazioni sull'azienda
| Fondato | I dipendenti | AMMINISTRATORE DELEGATO | Sito web |
|---|---|---|---|
| 2000 | 77 | Sofia Heigis | www.oncopeptides.com/sv |
Oncopeptides AB (publ), azienda biotecnologica, è impegnata nella ricerca, nello sviluppo e nella commercializzazione di terapie mirate per malattie ematologiche difficili da trattare negli Stati Uniti, in Europa e a livello internazionale. Il suo candidato principale è Pepaxti (melflufen), un farmaco coniugato per il trattamento del mieloma multiplo refrattario recidivato in pazienti adulti. La sua piattaforma PDC è stata progettata con due componenti, un vettore peptidico e un carico utile citotossico che utilizza il metabolismo alterato delle cellule tumorali per idrolizzare il PDC in metaboliti idrofili attivi, che portano a un arricchimento nelle cellule tumorali.
Oncopeptides AB (publ) Riepilogo dei fondamenti
| ONCO statistiche fondamentali | |
|---|---|
| Capitalizzazione di mercato | SEK 623.76m |
| Utili (TTM) | -SEK 221.10m |
| Ricavi(TTM) | SEK 83.24m |
7.5x
Rapporto P/S-2.8x
Rapporto P/EONCO è sopravvalutato?
Vedi Fair Value e analisi di valutazioneUtili e ricavi
| ONCO Conto economico (TTM) | |
|---|---|
| Ricavi | SEK 83.24m |
| Costo del fatturato | SEK 2.86m |
| Profitto lordo | SEK 80.38m |
| Altre spese | SEK 301.48m |
| Utili | -SEK 221.10m |
Ultimi utili riportati
Mar 31, 2026
Prossima data di guadagno
Aug 27, 2026
| Utile per azione (EPS) | -0.56 |
| Margine lordo | 96.57% |
| Margine di profitto netto | -265.63% |
| Rapporto debito/patrimonio netto | 170.3% |
Come si è comportato ONCO nel lungo periodo?
Vedi performance storica e confrontoAnalisi aziendale e situazione dei dati finanziari
| Dati | Ultimo aggiornamento (ora UTC) |
|---|---|
| Analisi dell'azienda | 2026/08/16 14:40 |
| Prezzo dell'azione a fine giornata | 2026/08/14 00:00 |
| Utili | 2026/03/31 |
| Utili annuali | 2025/12/31 |
Fonti dei dati
I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
| Pacchetto | Dati | Tempistica | Esempio Fonte USA * |
|---|---|---|---|
| Dati finanziari della società | 10 anni |
| |
| Stime di consenso degli analisti | +3 anni |
|
|
| Prezzi di mercato | 30 anni |
| |
| Proprietà | 10 anni |
| |
| Gestione | 10 anni |
| |
| Sviluppi principali | 10 anni |
|
* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.
Modello di analisi e Snowflake
I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina GitHub; abbiamo anche delle guide su come utilizzare i nostri report e dei tutorial su YouTube.
Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali
Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.
Fonti analitiche
Oncopeptides AB (publ) è coperta da 7 analisti. 3 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
| Analista | Istituzione |
|---|---|
| Erik Hultgård | Carnegie Investment Bank AB |
| Patrik Ling | DNB Carnegie |
| Erik Hultgård | DNB Carnegie |